FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892049154> ?p ?o ?g. }

• W2892049154 abstract "Data are limited on the benefits and risks of dose reduction in managing side effects associated with antipsychotic treatment. As an example, antipsychotic dose reduction has been recommended in the management of tardive dyskinesia (TD), yet the benefits of lowering doses are not well studied. However, stable maintenance treatment is essential to prevent deterioration and relapse in schizophrenia. A retrospective cohort study was conducted to analyze the healthcare burden of antipsychotic dose reduction in patients with schizophrenia. Medical claims from six US states spanning a six-year period were analyzed for ≥10% or ≥ 30% antipsychotic dose reductions compared with those from patients receiving a stable dose. Outcomes measured were inpatient admissions and emergency room (ER) visits for schizophrenia, all psychiatric disorders, and all causes, and TD claims. A total of 19,556 patients were identified with ≥10% dose reduction and 15,239 patients with ≥30% dose reduction. Following a ≥ 10% dose reduction, the risk of an all-cause inpatient admission increased (hazard ratio [HR] 1.17; 95% confidence interval [CI] 1.11, 1.23; P < 0.001), and the risk of an all-cause ER visit increased (HR 1.09; 95% CI 1.05, 1.14; P < 0.001) compared with controls. Patients with a ≥ 10% dose reduction had an increased risk of admission or ER visit for schizophrenia (HR 1.27; 95% CI 1.19, 1.36; P < 0.001) and for all psychiatric disorders (HR 1.16; 95% CI 1.10, 1.23; P < 0.001) compared with controls. A dose reduction of ≥30% also led to an increased risk of admission for all causes (HR 1.23; 95% CI 1.17, 1.31; P < 0.001), and for admission or ER visit for schizophrenia (HR 1.31; 95% CI 1.21, 1.41; P < 0.001) or for all psychiatric disorders (HR 1.21; 95% CI 1.14, 1.29; P < 0.001) compared with controls. Dose reductions had no significant effect on claims for TD. Patients with antipsychotic dose reductions showed significant increases in both all-cause and mental health–related hospitalizations, suggesting that antipsychotic dose reductions may lead to increased overall healthcare burden in some schizophrenia patients. This highlights the need for alternative strategies for the management of side effects, including TD, in schizophrenia patients that allow for maintaining effective antipsychotic treatment." @default.
• W2892049154 created "2018-09-27" @default.
• W2892049154 creator A5009613880 @default.
• W2892049154 creator A5039538880 @default.
• W2892049154 creator A5039966568 @default.
• W2892049154 creator A5048786351 @default.
• W2892049154 creator A5074273683 @default.
• W2892049154 creator A5080882152 @default.
• W2892049154 date "2018-09-24" @default.
• W2892049154 modified "2023-10-06" @default.
• W2892049154 title "Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia" @default.
• W2892049154 cites W1591577368 @default.
• W2892049154 cites W1896543281 @default.
• W2892049154 cites W1968943209 @default.
• W2892049154 cites W1969060266 @default.
• W2892049154 cites W1971123716 @default.
• W2892049154 cites W1975998171 @default.
• W2892049154 cites W1983341781 @default.
• W2892049154 cites W1989209269 @default.
• W2892049154 cites W1993796018 @default.
• W2892049154 cites W2005762752 @default.
• W2892049154 cites W2012190810 @default.
• W2892049154 cites W2017574928 @default.
• W2892049154 cites W2020845741 @default.
• W2892049154 cites W2032469488 @default.
• W2892049154 cites W2052854626 @default.
• W2892049154 cites W2074607197 @default.
• W2892049154 cites W2097900566 @default.
• W2892049154 cites W2103881007 @default.
• W2892049154 cites W2111703986 @default.
• W2892049154 cites W2129805955 @default.
• W2892049154 cites W2144555531 @default.
• W2892049154 cites W2166256285 @default.
• W2892049154 cites W2474394086 @default.
• W2892049154 cites W2582061582 @default.
• W2892049154 cites W2587942917 @default.
• W2892049154 cites W4235802159 @default.
• W2892049154 cites W4244009405 @default.
• W2892049154 cites W4246973800 @default.
• W2892049154 doi "https://doi.org/10.1186/s12888-018-1889-2" @default.
• W2892049154 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6154822" @default.
• W2892049154 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30249218" @default.
• W2892049154 hasPublicationYear "2018" @default.
• W2892049154 type Work @default.
• W2892049154 sameAs 2892049154 @default.
• W2892049154 citedByCount "18" @default.
• W2892049154 countsByYear W28920491542019 @default.
• W2892049154 countsByYear W28920491542020 @default.
• W2892049154 countsByYear W28920491542021 @default.
• W2892049154 countsByYear W28920491542022 @default.
• W2892049154 countsByYear W28920491542023 @default.
• W2892049154 crossrefType "journal-article" @default.
• W2892049154 hasAuthorship W2892049154A5009613880 @default.
• W2892049154 hasAuthorship W2892049154A5039538880 @default.
• W2892049154 hasAuthorship W2892049154A5039966568 @default.
• W2892049154 hasAuthorship W2892049154A5048786351 @default.
• W2892049154 hasAuthorship W2892049154A5074273683 @default.
• W2892049154 hasAuthorship W2892049154A5080882152 @default.
• W2892049154 hasBestOaLocation W28920491541 @default.
• W2892049154 hasConcept C118552586 @default.
• W2892049154 hasConcept C126322002 @default.
• W2892049154 hasConcept C167135981 @default.
• W2892049154 hasConcept C207103383 @default.
• W2892049154 hasConcept C2776412080 @default.
• W2892049154 hasConcept C2779134260 @default.
• W2892049154 hasConcept C2779158372 @default.
• W2892049154 hasConcept C2779734285 @default.
• W2892049154 hasConcept C2780405171 @default.
• W2892049154 hasConcept C2780494398 @default.
• W2892049154 hasConcept C44249647 @default.
• W2892049154 hasConcept C71924100 @default.
• W2892049154 hasConceptScore W2892049154C118552586 @default.
• W2892049154 hasConceptScore W2892049154C126322002 @default.
• W2892049154 hasConceptScore W2892049154C167135981 @default.
• W2892049154 hasConceptScore W2892049154C207103383 @default.
• W2892049154 hasConceptScore W2892049154C2776412080 @default.
• W2892049154 hasConceptScore W2892049154C2779134260 @default.
• W2892049154 hasConceptScore W2892049154C2779158372 @default.
• W2892049154 hasConceptScore W2892049154C2779734285 @default.
• W2892049154 hasConceptScore W2892049154C2780405171 @default.
• W2892049154 hasConceptScore W2892049154C2780494398 @default.
• W2892049154 hasConceptScore W2892049154C44249647 @default.
• W2892049154 hasConceptScore W2892049154C71924100 @default.
• W2892049154 hasFunder F4320308970 @default.
• W2892049154 hasIssue "1" @default.
• W2892049154 hasLocation W28920491541 @default.
• W2892049154 hasLocation W28920491542 @default.
• W2892049154 hasLocation W28920491543 @default.
• W2892049154 hasLocation W28920491544 @default.
• W2892049154 hasOpenAccess W2892049154 @default.
• W2892049154 hasPrimaryLocation W28920491541 @default.
• W2892049154 hasRelatedWork W1521360283 @default.
• W2892049154 hasRelatedWork W1645692048 @default.
• W2892049154 hasRelatedWork W2004303197 @default.
• W2892049154 hasRelatedWork W2016227631 @default.
• W2892049154 hasRelatedWork W2016587188 @default.
• W2892049154 hasRelatedWork W2022873348 @default.
• W2892049154 hasRelatedWork W2182619966 @default.
• W2892049154 hasRelatedWork W2331261172 @default.
• W2892049154 hasRelatedWork W2566890669 @default.

• next